Seer announces CFO transition. September 21, 2026 07:00 ET | Source: Seer, Inc. REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) - Seer, Inc. (Nasdaq: SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company's President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company. Charles Endweiss, who has been Seer's Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financial officer and principal accounting officer, effective October 1, 2026. "David has been an important member of Seer's leadership team for more than six years, helping guide the Company through a pivotal period," said Omid Farokhzad, M.D., Chair and Chief Executive Officer of Seer. "We are grateful for David's many contributions and wish him all the best in his next chapter." Dr. Farokhzad added, "Charles has been a trusted member of Seer's finance organization for nearly five years and brings the financial expertise, leadership and deep understanding of our business that are critical to our continued progress. We are confident he will play an important role in continuing our efforts to position Seer for long-term success." "It has been a privilege to work alongside Omid and the entire Seer team over the past six years," said Mr. Horn. "I am proud of what we have accomplished together and remain confident in the team, Seer's differentiated technology and the opportunity ahead for the Company. I have worked closely with Charles Endweiss and am confident he will be a strong steward of the finance team. I look forward to following the Company's continued success." About Charles Endweiss Charles Endweiss, age 49, has served as the Company's Vice President, Financial Planning & Analysis since January 2021. Prior to joining the Company, Mr. Endweiss served as Head of Business Operations, Oral Health at Carbon, a provider of end-to-end digital 3D printing and manufacturing platform, from August 2017 to January 2021. Earlier in his career, Mr. Endweiss held a range of accounting, finance, and business operations positions at various technology companies. He holds a B.A. in Business from the University of Illinois, Urbana-Champaign and an M.B.A. from Santa Clara University. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph(R) Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements relating to the transition in finance and accounting roles at the Company. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Media Contact: Patrick Schmidt [email protected] Investor Contact: Marissa Bych [email protected]

Seer reported revenue of $3.1 million for the second quarter of 2026, a 23% decrease from $4.1 million in the prior year period. The company attributed the decline to macroeconomic headwinds affecting academic and government funding, along with extended customer evaluations. The proteomics company posted a net loss of $16.9 million for the quarter, compared to $19.4 million in the year-ago period. Operating expenses decreased 19% to $18.3 million, primarily due to lower employee compensation costs. Seer ended the quarter with approximately $209.5 million in cash, cash equivalents, and investments. The company repurchased roughly 200,000 Class A common shares during the period. Seer reaffirmed its full year 2026 revenue guidance of $16 million to $18 million, representing 3% growth over 2025.

Seer (NASDAQ:SEER) issues quarterly earnings results, misses estimates by $0.04 EPS. August 11, 2026 Key points. * Seer missed quarterly expectations: The company reported an adjusted loss of $0.31 per share, $0.04 worse than analysts' estimate, while revenue of $3.10 million fell short of the $3.55 million consensus. * Profitability remains weak: Seer posted a negative 26.58% return on equity and a negative net margin of 464.78%, highlighting continued operating losses. * Analyst sentiment is mixed but leans positive: The stock has a consensus "Buy" rating and a $4.00 average price target, although one analyst maintained a "Sell" rating. Institutional investors own 75.20% of the shares. * MarketBeat previews the top five stocks to own by September 1st. Seer (NASDAQ:SEER - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.04), FiscalAI reports. Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.55 million. Seer stock performance. NASDAQ SEER remained flat at $2.16 on Tuesday. 199,128 shares of the company's stock traded hands, compared to its average volume of 644,225. The business has a 50-day moving average of $1.94 and a two-hundred day moving average of $1.88. The company has a market capitalization of $118.76 million, a PE ratio of -1.74 and a beta of 1.55. Seer has a fifty-two week low of $1.55 and a fifty-two week high of $2.41. Institutional inflows and outflows. Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Seer by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company's stock worth $4,820,000 after acquiring an additional 18,760 shares during the period. Bridgeway Capital Management LLC lifted its stake in Seer by 15.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company's stock valued at $1,792,000 after acquiring an additional 112,100 shares during the period. Geode Capital Management LLC lifted its stake in Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company's stock valued at $1,091,000 after acquiring an additional 72,265 shares during the period. Jane Street Group LLC boosted its holdings in shares of Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company's stock valued at $430,000 after acquiring an additional 63,432 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Seer by 2.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company's stock valued at $431,000 after acquiring an additional 6,304 shares during the last quarter. 75.20% of the stock is owned by institutional investors and hedge funds. Wall Street analysts forecast growth. A number of research analysts have recently commented on the stock. TD Cowen upgraded shares of Seer to a "strong-buy" rating in a report on Monday, April 13th. Canaccord Genuity Group began coverage on shares of Seer in a research note on Monday, May 4th. They issued a "buy" rating and a $4.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Seer in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Seer currently has a consensus rating of "Buy" and an average target price of $4.00. Seer company profile. Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine. The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Seer, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list. While Seer currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.